EGFR and lung cancer: On the other hand, EGFR blockers—including small kinase inhibitors such as erlotinib, gefitinib, or afatinib, or monoclonal antibodies—have been used in several human proliferative disorders, including lung cancer [65,66,67,68,69,70], opening novel opportunities to use EGFR blockers in renal diseases.